Diabetes: Advances in treatment

Internal Medicine Journal

Volumn 37, Issue 6, 2007, Pages 383-388

  Cohen, N D ^a   Shaw, J E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Diabetes; Diagnosis; Prevention; Therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ASPART; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; NICOTINAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; UNCLASSIFIED DRUG;

CELL REGENERATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DIABETES MELLITUS; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOMODULATION; IMPAIRED GLUCOSE TOLERANCE; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; T LYMPHOCYTE; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN INFUSION SYSTEMS; RISK REDUCTION BEHAVIOR;

EID: 34447103622     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01369.x     Document Type: Review

References (35)

1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 1998 21 : 1138 45.
2. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002 25 : 829 34.
3. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006 29 Suppl. 1 : S4 S42.
4. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003 26 : 3160 7.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
6. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005 54 : 1150 6.
7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 344 : 1343 50.
8. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997 20 : 537 44.
9. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 : 1096 105.
10. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002 51 : 2796 803.
11. Chiasson JL, Brindisi MC, Rabasa-Lhoret R. The prevention of type 2 diabetes: what is the evidence? Minerva Endocrinol 2005 30 : 179 91.
12. Eriksson JG, Lehtovirta M, Ehrnstrom B, Salmela S, Groop L. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. J Intern Med 2006 259 : 553 60.
13. Gillespie KM. Type 1 diabetes: pathogenesis and prevention. CMAJ 2006 175 : 165 70.
14. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H et al. Implications of the United Kingdom prospective diabetes study. Diabetes Care 2003 26 Suppl. 1 : S28 S32.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 86.
16. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
17. Bryant W, Greenfield JR, Chisholm DJ, Campbell LV. Diabetes guidelines: easier to preach than to practise? Med J Aust 2006 185 : 305 9.
18. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 317 : 703 13.
19. Kendall DM. Thiazolidinediones: the case for early use. Diabetes Care 2006 29 : 154 7.
20. Fonarow GC. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J 2004 148 : 551 8.
21. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 89.
22. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004 47 : 357 66.
23. Drucker DJ. The biology of incretin hormones. Cell Metab 2006 3 : 153 65.
24. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006 49 : 253 60.
25. Hirsch IB. Insulin analogues. N Engl J Med 2005 352 : 174 83.
26. Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract 2005 11 : 11 17.
27. Garg SK. New insulin analogues. Diabetes Technol Ther 2005 7 : 813 17.
28. Fabbri L. Pulmonary safety of inhaled insulins: a review of the current data. Curr Med Res Opin 2006 22 Suppl. 3 : 21 8.
29. Trubo R. Interest in inhaled insulin grows. JAMA 2005 294 : 1195 6.
30. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002 324 : 705 10.
31. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003 26 : 1079 87.
32. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med 2006 23 : 1 12.
33. Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet transplant. Diabetes Obes Metab 2006 8 : 1 7.
34. Nanji SA, Shapiro AM. Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab 2006 8 : 15 25.
35. Merani S, Shapiro AM. Current status of pancreatic islet transplantation. Clin Sci (Lond) 2006 110 : 611 25.